The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of cafelkibart (LM-108), an anti-CCR8 monoclonal antibody, in combination with anti-PD-1 therapy in patients with pancreatic cancer: Results from phase 1/2 studies.
 
Jifang Gong
No Relationships to Disclose
 
Chang Liu
No Relationships to Disclose
 
Liang Liu
No Relationships to Disclose
 
Jun Yao
No Relationships to Disclose
 
Yiping Mou
No Relationships to Disclose
 
Jing Dai
No Relationships to Disclose
 
Youshan Chen
No Relationships to Disclose
 
Xiuli Yang
No Relationships to Disclose
 
Mihitha Ariyapperuma
Research Funding - Adagene; AstraZeneca; BeiGene; Biothera; BMS Norway; LaNova Australia; MSD Oncology
Travel, Accommodations, Expenses - MSD Oncology
 
Yiping Zhang
No Relationships to Disclose
 
Junli Xue
No Relationships to Disclose
 
Jermaine Coward
No Relationships to Disclose
 
Yun Zhou
No Relationships to Disclose
 
Yinghua Ji
Research Funding - AoSaiKang (Inst); CSPC Pharmaceutical Group (Inst); Hualan Bio (Inst)
 
Qingshan Li
No Relationships to Disclose
 
Rusen Zhao
No Relationships to Disclose
 
Zhizhen Zhu
No Relationships to Disclose
 
Ben Markman
Consulting or Advisory Role - AstraZeneca; Greywolf Therapeutics
 
Haoyuan Li
No Relationships to Disclose
 
Lin Shen
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; MSD; SERVIER; Transcenta Holding Limited
Research Funding - BeiGene (Inst)